Abstract On July 7, 2020, the Food and Drug Administration approved Inqovi (Otsuka
Pharmaceutical Co.), an oral fixed-dose combination tablet comprising 35 mg decitabine, a …

Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine,
are used extensively in the treatment of myelodysplastic syndromes and acute myeloid …

Myelodysplastic syndromes (MDS) treated with DNMTI therapy have responses according to
the 2006 IWG response criteria. CR responses have had the strongest association with OS …

Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic
mutations that are known or suspected to be oncogenic in the malignant cells. The genetic …

The current gold standard of response assessment in patients with myelodysplastic
syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia …

Introduction Myelodysplastic syndromes (MDS) are heterogeneous group of clonal
hematopoietic stem cell neoplasms that have limited approved treatment options. Multiple …

Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid
neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an …

Current Treatment Options in Oncology not a clear standard of care. For those without
previous luspatercept exposure it can be considered particularly if there is an SF3B1 …

Myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid
leukaemia comprise a spectrum of heterogenous myeloid diseases characterised by …

Higher-risk myelodysplastic syndromes (HR-MDS) are characterized by an increased risk of
acute myeloid leukemia (AML) transformation and compromised overall survival (OS)[1, 2] …